Chiedu Ogwu, MD
Internal Medicine · Lancaster, TXNPI 1669855250
Payments from drug & device makers
Across 261 payments — averaging $19.09 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$1K
- AstraZeneca$993
- GSK$510
- Lilly USA, LLC$368
- Boehringer Ingelheim$287
- Indivior Inc.$244
- plus $1K from 25 others
What the payments were for
- Food & beverage$4,969100%
- Education$130%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 75 | $1,356 |
| AstraZeneca | 52 | $993 |
| GSK | 31 | $510 |
| Lilly USA, LLC | 26 | $368 |
| Boehringer Ingelheim | 13 | $287 |
| Indivior Inc. | 5 | $244 |
| Pfizer | 4 | $164 |
| Orexo US, Inc. | 8 | $131 |
| Abbott | 6 | $130 |
| Exact Sciences | 5 | $94 |
| Dexcom, Inc. | 5 | $79 |
| Sanofi-aventis U.S. LLC | 3 | $66 |
| Corcept Therapeutics | 2 | $60 |
| Inspire Medical Systems, Inc. | 2 | $57 |
| Xeris Pharmaceuticals, Inc. | 3 | $56 |
| Bayer | 3 | $53 |
| Amgen | 2 | $41 |
| Astellas Pharma US Inc | 2 | $36 |
| Merck | 2 | $31 |
| Kowa Pharmaceuticals America, Inc. | 1 | $23 |
| Amarin Pharma, Inc. | 1 | $23 |
| Biohaven Pharmaceuticals, Inc. | 1 | $20 |
| AbbVie | 1 | $20 |
| Sanofi Pasteur Inc. | 1 | $20 |
| Hologic Sales And Service, LLC | 1 | $19 |
| Verona Pharma, Inc. | 1 | $19 |
| Neotract Inc. | 1 | $18 |
| Medtronic | 1 | $18 |
| Genentech USA, Inc. | 1 | $15 |
| Johnson & Johnson | 1 | $15 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 1 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$4,982 in reported general payments places this provider in the 85th percentile of 7,675 internal medicine providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 175 | $278,007 |
| EliquisApixaban | 70 | $88,728 |
| SuboxoneBuprenorphine Hcl/Naloxone Hcl | 103 | $76,699 |
| MounjaroTirzepatide | 45 | $74,318 |
| FarxigaDapagliflozin Propanediol | 52 | $63,157 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 63 | $58,310 |
| JardianceEmpagliflozin | 41 | $53,243 |
| TrulicityDulaglutide | 20 | $42,492 |
| LinzessLinaclotide | 42 | $32,131 |
| Tresiba Flextouch U-200Insulin Degludec | 24 | $30,579 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 34 | $24,482 |
| XareltoRivaroxaban | 15 | $19,351 |
| Buprenorphine-NaloxoneBuprenorphine Hcl/Naloxone Hcl | 61 | $13,043 |
| SymbicortBudesonide/Formoterol Fumarate | 30 | $8,792 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 271 | $8,738 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,356 | $278,007175 claims |
| Lilly USA, LLCMounjaro, Trulicity, Humulin 70-30 | $368 | $118,91781 claims |
| AstraZenecaFarxiga, Breztri Aerosphere, Symbicort | $993 | $96,431116 claims |
| PfizerEliquis | $164 | $88,72870 claims |
| Indivior Inc.Suboxone | $244 | $76,699103 claims |
| GSKTrelegy Ellipta | $510 | $58,31063 claims |
| Boehringer IngelheimJardiance | $287 | $53,24341 claims |
| AbbVieLinzess | $20 | $32,13142 claims |
| Johnson & JohnsonXarelto | $15 | $19,35115 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 7,675 internal medicine providers in Texas.
Other internal medicine in Lancaster
- Jan BurgerHouston$47.3M
- Nitin JainHouston$33.2M
- Muhammad IrfanTomball$30.6M
- Aung NaingHouston$30.6M
- Robert BassSan Antonio$25.6M
- Preetesh JainHouston$19.5M
- Paolo StratiHouston$19.2M
- Hernan SalazarSan Antonio$18.5M
- Nicholas ShortHouston$17.6M
- Salma SaigerMesquite$16.1M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.